Positive clinical trial results are a significant driver of biopharmaceutical company stock prices. Given that IGC-AD1 has shown to clinically reduce Alzheimer's agitation compared to a placebo, investor optimism is likely to increase, potentially leading to a short-term rise in IGC's stock price. The announcement reaffirms previous positive news, adding to its credibility and the potential for a positive market reaction.